AbInitio Bio
YC X26Boston, US · Founded 2026 · 2 employees · 1 known investors
AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.
Founders & leadership· Y Combinator alumni (X26)
AbInitio Bio was founded in 2026 by Daniel Mukasa and Nisha Gopal.
DM
Daniel Mukasain𝕏FounderDaniel Mukasa holds a PhD in Applied Physics and Materials Science from Caltech and completed postdoctoral work at MIT on AI and drug discovery applications. He previously worked as an AI/ML intern at Merck on antibody therapeutic design, and is now founder and CEO of AbInitio Bio.
NG
Nisha GopalinCo-Founder & CSONisha Gopal holds a PhD in biochemistry from Stanford and brings 14 years of research experience, including prior work as a research scientist at the Broad Institute. She is founder and Chief Scientific Officer of AbInitio Bio.
Investors · 1
Competitors · 5
by search overlap
bio8 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
Avidbio6 shared keywordsAvid Bioservices is a U.S.-based contract development and manufacturing organization (CDMO) specializing in mammalian cell culture process development, analytical development, and CGMP biologics manufacturing. It serves biopharma companies across the full biologics lifecycle, from DNA to IND to commercial supply, operating FDA-inspected facilities in California.
Actio Biosciences, Inc.4 shared keywordsActio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.
iBio4 shared keywordsiBio discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies against hard-to-drug targets. The company operates in the biotech and drug discovery space.
Infinant Health3 shared keywordsInfinant Health develops probiotic products based on B. infantis strains that work with breast milk to support the infant gut microbiome, including its INF108 drug strain aimed at preventing necrotizing enterocolitis (NEC) in premature infants. The company operates in the infant health and microbiome therapeutics space.
Companies competing with AbInitio Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does AbInitio Bio do?
- AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.
- Who founded AbInitio Bio?
- AbInitio Bio was founded by Daniel Mukasa, Nisha Gopal in 2026.
- Who are AbInitio Bio's investors?
- AbInitio Bio's investors include Y Combinator.
- Where is AbInitio Bio headquartered?
- AbInitio Bio is headquartered in Boston, US.